CN104023747A - 用于癌症治疗的伊珠单抗奥佐米星和torisel的组合 - Google Patents

用于癌症治疗的伊珠单抗奥佐米星和torisel的组合 Download PDF

Info

Publication number
CN104023747A
CN104023747A CN201280062130.7A CN201280062130A CN104023747A CN 104023747 A CN104023747 A CN 104023747A CN 201280062130 A CN201280062130 A CN 201280062130A CN 104023747 A CN104023747 A CN 104023747A
Authority
CN
China
Prior art keywords
cancer
carcinoma
pharmaceutically acceptable
pharmaceutical composition
cci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280062130.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·布吕德勒
P·莫兰
A·斯塔西斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
Pfizer Inc
Original Assignee
ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND, Pfizer Inc filed Critical ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
Publication of CN104023747A publication Critical patent/CN104023747A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201280062130.7A 2011-12-16 2012-12-04 用于癌症治疗的伊珠单抗奥佐米星和torisel的组合 Pending CN104023747A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576831P 2011-12-16 2011-12-16
US61/576,831 2011-12-16
PCT/IB2012/056958 WO2013088304A1 (en) 2011-12-16 2012-12-04 Combination of inotuzumab ozogamicin and torisel for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN104023747A true CN104023747A (zh) 2014-09-03

Family

ID=47557418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280062130.7A Pending CN104023747A (zh) 2011-12-16 2012-12-04 用于癌症治疗的伊珠单抗奥佐米星和torisel的组合

Country Status (13)

Country Link
US (1) US9642918B2 (https=)
EP (1) EP2790723A1 (https=)
JP (1) JP2013126979A (https=)
KR (2) KR20170049617A (https=)
CN (1) CN104023747A (https=)
AU (2) AU2012351728A1 (https=)
BR (1) BR112014014181A2 (https=)
CA (1) CA2859089A1 (https=)
HK (1) HK1201191A1 (https=)
IL (1) IL233165A0 (https=)
MX (1) MX2014007077A (https=)
RU (1) RU2607594C2 (https=)
WO (1) WO2013088304A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110998319A (zh) * 2017-06-06 2020-04-10 约翰霍普金斯大学 用表观遗传疗法诱导合成致死性

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016201481A1 (en) * 2015-06-15 2016-12-22 Newsouth Innovations Pty Limited Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
AU2020221271A1 (en) * 2019-02-13 2021-10-07 Coimmune, Inc. Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
MX2022004326A (es) * 2019-10-10 2022-07-27 Bryologyx Inc Método para la inducción de antígenos asociados al tumor con briostatina.
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415409A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂的组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4667637A (en) 1986-01-08 1987-05-26 Brunswick Corporation Gated knock detector for internal-combustion engines
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
WO2007125252A1 (fr) 2006-04-26 2007-11-08 France Telecom Procede et systeme de gestion d'un paiement electronique
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
RU2585489C2 (ru) * 2010-04-27 2016-05-27 Рош Гликарт Аг КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415409A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂的组合

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K. TAY ET AL.: "Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise", 《BLOOD REVIEWS》, vol. 24, no. 2, 31 December 2010 (2010-12-31), pages 69 - 82, XP 026923268, DOI: doi:10.1016/j.blre.2010.01.001 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110998319A (zh) * 2017-06-06 2020-04-10 约翰霍普金斯大学 用表观遗传疗法诱导合成致死性
US12419900B2 (en) 2017-06-06 2025-09-23 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy

Also Published As

Publication number Publication date
BR112014014181A2 (pt) 2017-06-13
HK1201191A1 (en) 2015-08-28
KR20170049617A (ko) 2017-05-10
CA2859089A1 (en) 2013-06-20
IL233165A0 (en) 2014-07-31
JP2013126979A (ja) 2013-06-27
MX2014007077A (es) 2015-03-06
WO2013088304A1 (en) 2013-06-20
EP2790723A1 (en) 2014-10-22
AU2012351728A1 (en) 2014-06-19
AU2016202621B2 (en) 2017-11-02
RU2607594C2 (ru) 2017-01-10
RU2014124005A (ru) 2016-02-10
KR20140107413A (ko) 2014-09-04
US20140335109A1 (en) 2014-11-13
AU2016202621A1 (en) 2016-05-26
US9642918B2 (en) 2017-05-09

Similar Documents

Publication Publication Date Title
CN104023747A (zh) 用于癌症治疗的伊珠单抗奥佐米星和torisel的组合
CN101287475B (zh) 包含透明质酸和治疗抗体的治疗组合物以及制药用途
US20230235083A1 (en) Combination therapy using a liv1-adc and a chemotherapeutic
Morscher et al. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial
CN107106685A (zh) 协同澳瑞他汀组合
JP2014515390A (ja) Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
CN114302746A (zh) 包含抗cd25抗体药物缀合物和另一剂的组合疗法
JP2022533100A (ja) Ｎｏｔｃｈ活性化乳がんを治療するためのビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物
US20240366569A1 (en) Combinations for treating cancer
JP7504106B2 (ja) がんの処置のための組合せ物
AU2021271808A1 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD38 antibodies
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
Tarapore ACTR-33. Tumor Tissue Penetration and Pharmacodynamics of ONC201 in Adult Recurrent Glioblastoma Patients
EP4705341A1 (en) Combinations for treating cancer
WO2023039568A1 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors
CN116265030A (zh) 包含酪氨酸激酶抑制剂德立替尼的药物组合
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
JP2016518400A (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201191

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20140903

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201191

Country of ref document: HK